B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15

Journey Medical Corp.

Journey Medical Corp.

DERM

0.00

B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ: DERM) with a Buy and raises the price target from $12 to $15.